Quantitative mRNA Capping Efficiency via Chromatographic Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing mRNA capping efficiency are qualitative and do not allow for quantification without altering the mRNA, which is inadequate for ensuring the quality and safety of mRNA-based therapeutic products.
Innovation Solution
A method involving the generation and separation of capped and uncapped mRNA fragments using chromatography, where a DNA oligonucleotide anneals to the mRNA and nucleases degrade the hybrid, allowing for the quantification of capping efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If qualitative cap assays are used, then the method is simple, but the measurement precision is insufficient for assessing mRNA quality and safety
Solution Approach 1:
The mRNA sample is segmented into capped and uncapped fragments through selective nuclease digestion. The DNA oligonucleotide anneals to a specific region of the mRNA, and nucleases selectively degrade the hybrid DNA-RNA structure, separating capped from uncapped mRNA fragments for quantitative analysis by chromatography.
Solution Approach 2:
A DNA oligonucleotide serves as an intermediary that anneals to the mRNA sample. This intermediary enables selective degradation by nucleases and facilitates subsequent chromatographic separation, allowing quantitative measurement of capping efficiency without permanently altering the mRNA.
2Measurement precision
If permanent alterations are made to mRNA to enable quantification, then measurement precision improves, but the reliability of the mRNA for therapeutic use is compromised
Solution Approach 1:
Only a partial portion of the mRNA is altered through selective nuclease digestion of the DNA-RNA hybrid. The annealing of the DNA oligonucleotide creates a localized region that can be selectively degraded, allowing quantification of capping efficiency while leaving the majority of the mRNA population intact and suitable for therapeutic use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a reliable and efficient quantitative method for assessing mRNA capping efficiency, essential for quality control and ensuring the efficacy of mRNA therapeutic products.
Implementation Method 1
contacting the mRNA sample with a DNA oligonucleotide complimentary to a sequence in the 5′ untranslated region of the mRNA adjacent to the cap or uncapped penultimate base of mRNA under conditions that permit the DNA oligonucleotide anneal to the sequence
Implementation Method 2
providing one or more nucleases that selectively degrade DNA/RNA hybrid and/or unannealed mRNA, resulting in capped and uncapped fragments
Implementation Method 3
separating the capped and uncapped fragments by chromatography
Data Source
AI summary
The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly for mRNA synthesized in vitro. In some embodiments, the methods comprise chromatographic methods of quantifying capping efficiency and methylation status of the caps.